For research use only. Not for therapeutic Use.
ML-290 is a first-in-class and potent relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM[1]. ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.
ML-290 is a first-in-class and potent relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM[1].?
ML290 (5 μM) shows anti-fibrotic, relaxin-like gene expression at 24 and 72 h in activated human hepatic stellate cells[1].
| Catalog Number | I008092 |
| CAS Number | 1482500-76-4 |
| Synonyms | 2-[(2-propan-2-yloxybenzoyl)amino]-N-[3-(trifluoromethylsulfonyl)phenyl]benzamide |
| Molecular Formula | C24H21F3N2O5S |
| Purity | ≥95% |
| InChI | InChI=1S/C24H21F3N2O5S/c1-15(2)34-21-13-6-4-11-19(21)23(31)29-20-12-5-3-10-18(20)22(30)28-16-8-7-9-17(14-16)35(32,33)24(25,26)27/h3-15H,1-2H3,(H,28,30)(H,29,31) |
| InChIKey | RSYHJSDOGMSLDH-UHFFFAOYSA-N |
| SMILES | CC(C)OC1=CC=CC=C1C(=O)NC2=CC=CC=C2C(=O)NC3=CC(=CC=C3)S(=O)(=O)C(F)(F)F |
| Reference | [1]. Wilson KJ, et al. Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. Eur J Med Chem. 2018 Aug 5;156:79-92. |
